Genelabs To Meet With FDA Following Positive Open-Label Prestara Study
This article was originally published in The Pink Sheet Daily
Executive Summary
The study was an extension of a previous Phase III study that failed to meet its primary endpoint of increased bone mineral density at the lumbar spine.